Carmell Co. (NASDAQ:CTCX) Sees Significant Decline in Short Interest

Carmell Co. (NASDAQ:CTCXGet Free Report) was the recipient of a large decline in short interest in August. As of August 31st, there was short interest totalling 55,400 shares, a decline of 5.5% from the August 15th total of 58,600 shares. Currently, 0.4% of the shares of the stock are short sold. Based on an average trading volume of 27,300 shares, the short-interest ratio is presently 2.0 days.

Carmell Price Performance

Shares of NASDAQ CTCX opened at $0.43 on Wednesday. The business has a fifty day moving average price of $0.94 and a two-hundred day moving average price of $1.81. Carmell has a fifty-two week low of $0.43 and a fifty-two week high of $4.99.

Carmell (NASDAQ:CTCXGet Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.16) earnings per share for the quarter. The business had revenue of $0.01 million during the quarter.

Hedge Funds Weigh In On Carmell

A hedge fund recently bought a new stake in Carmell stock. Hubbell Strickland Wealth Management LLC purchased a new stake in Carmell Co. (NASDAQ:CTCXFree Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 12,548 shares of the company’s stock, valued at approximately $32,000. Hubbell Strickland Wealth Management LLC owned about 0.07% of Carmell as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 24.22% of the company’s stock.

Carmell Company Profile

(Get Free Report)

Carmell Corporation operates as a bio-aesthetics company. The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks. The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.

Featured Stories

Receive News & Ratings for Carmell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carmell and related companies with MarketBeat.com's FREE daily email newsletter.